Patents Examined by Jeffrey E. Russel
  • Patent number: 11213570
    Abstract: Methods for the treatment or prevention of disease, such as fatty liver disease and obesity, are described including the modulation the amount of CTRP1 in a subject. Novel mouse strains are also described.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: January 4, 2022
    Assignee: The Johns Hopkins University
    Inventors: Guang William Wong, Susana Rodriguez
  • Patent number: 11214593
    Abstract: The present invention provides a peptide of formula (I), or a pharmaceutically acceptable salt thereof, wherein the N-terminal group of the peptide is a monoradical of formula —NHR1; the C-terminal group of the peptide is a monoradical of formula —C(O)—R2; R1 is a monoradical selected from hydrogen and —C(O)—(C1-C20)alkyl; R2 is a monoradical selected from —OH and —NR3R4 radical; R3 and R4 are independently selected from hydrogen and (C1-C10)alkyl; “a” to “j” are integers from 0 to 1, provided that at least one of “a” to “j” is 1; and X1 represents any amino acid. The present invention also provides conjugates and compositions comprising the peptide of formula (I). The peptide can be used in the treatment or prevention of neoplastic diseases such as pancreatic cancer.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: January 4, 2022
    Assignee: SUIGENERIS FARMACOSMETICS, S.L.
    Inventor: Teresa Royo Bargués
  • Patent number: 11208645
    Abstract: The present invention relates to variants of factor IX (F.IX) or activated factor IX (F.IXa), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to variants of factor IX (F.IX) or activated factor IX (F.IXa), wherein the variant is characterized in that it has increased F.IX clotting activity compared to wildtype. The present invention furthermore relates to the use of these variants for the treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: December 28, 2021
    Assignee: DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH
    Inventors: Jörg Schüttrumpf, Patricia Quade-Lyssy, Peter Milanov, Erhard Seifried
  • Patent number: 11208459
    Abstract: The present disclosure features signal-regulatory protein ? (SIRP-?) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-? constructs include a high affinity SIRP-? D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-?. The SIRP-? polypeptides or constructs include a SIRP-? D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein ? (SIRP-?) D1 variant and (ii) an antibody.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: December 28, 2021
    Assignee: ALX Oncology Inc.
    Inventors: Jaume Pons, Bang Janet Sim, Steven Elliot Kauder, Hong Wan, Tracy Chia-Chien Kuo
  • Patent number: 11198713
    Abstract: Among other things, the present disclosure provides technologies for modulating functions of beta-catenin. In some embodiments, the present disclosure provides stapled peptides that interact with beta-catenin. In some embodiments, provided stapled peptides interact with beta-catenin at an Axin-binding site of beta-catenin. In some embodiments, the present disclosure provides compounds, compositions and methods for preventing and/or treating conditions, disorders and diseases that are associated with beta-catenin.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: December 14, 2021
    Assignee: FOG PHARMACEUTICALS, INC.
    Inventors: Gerard Hilinski, So Youn Shim, Matthew Reiser Patton, John Hanney McGee, Paula Ortet, Gregory L. Verdine
  • Patent number: 11197909
    Abstract: The disclosure features non-irritating pharmaceutical compositions containing CD101 in pharmaceutical acceptable salt (e.g., CD101 acetate) or neutral form. The pharmaceutical compositions can be intravenously administered to a subject to treat fungal infections (e.g., candidiasis) in the subject.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: December 14, 2021
    Assignee: Cidara Therapeutics, Inc.
    Inventors: Kenneth Bartizal, Paul Daruwala, David Hughes, Martin Patrick Hughes, Navdeep B. Malkar, Balasingam Radhakrishnan, Anuradha Vaidya
  • Patent number: 11191810
    Abstract: The present invention provides a pharmaceutical formulation comprising LL-37 or a pharmaceutically-acceptable salt thereof and one or more pharmaceutically-acceptable diluent or carrier system, for use in a method of treatment of a chronic ulcer wound (such as a hard-to-heal venous leg ulcer or a diabetic foot ulcer), which method comprises: (a) topical application of the formulation to the ulcer; followed by (b) application of a dressing, and wherein the application of the formulation provides for a dose of LL-37 at the wound site that is below about 80 ?g of LL-37 applied per cm2 of wound area, and/or below about 26.7 ?g of LL-37 applied per cm2 of wound area, per day of treatment.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: December 7, 2021
    Assignee: Promore Pharma AB
    Inventors: Alvar Grönberg, Christine Dieterich, Margit Mahlapuu
  • Patent number: 11191773
    Abstract: This invention features new compositions and methods that are useful in treating a host with a Gram-negative bacterial infection. Combination therapies comprising an aminocoumarin compound and a polymyxin compound are disclosed, including certain combinations that exhibit synergistic effects. Furthermore, aminocoumarin compounds are described having altered inhibition of DNA gyrase in Gram-negative bacteria and/or the ability to target the transport proteins responsible for assembling lipopolysaccharide in the outer membrane of Gram-negative bacteria.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: December 7, 2021
    Assignees: President and Fellows of Harvard College, The Ohio State University
    Inventors: Daniel E. Kahne, Michael D. Mandler, Vadim Baidin, Natividad Ruiz
  • Patent number: 11174283
    Abstract: The present disclosure pertains to compositions comprising aflibercept and methods for producing such compositions in chemically defined media and using chromatography to reduce amounts of certain aflibercept variants.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: November 16, 2021
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Andrew Tustian, Ankit Vartak, Thomas Daly, Erica Pyles, Nisha Palackal, Shunhai Wang, Ning Li
  • Patent number: 11161875
    Abstract: In fibrotic lung fibroblasts, basal levels of p53 protein (and miR-34a) are markedly suppressed, leading to reduced p53-mediated inhibition of uPA and uPAR, or concurrent induction of PAI-1. These changes contribute to excessive FL-fibroblast proliferation and production of extracellular matrix (ECM), and, therefore, pulmonary fibrosis. These processes are reversed by treating the cells, and treating subjects suffering from idiopathic pulmonary fibrosis (IPF) with the small organic molecule nutlin-3a (NTL) or with a peptide, CSP-4 (SEQ ID NO:1), or variants or derivatives or multimers of this peptide, which increase p53 levels by inhibiting MDM2-mediated degradation of p53 protein. Use of these compounds serves as a new approach to the treatment of IPF, as they restore p53 expression and p53-mediated changes in the uPA-fibrinolytic system in FL-fibroblasts and restrict production and deposition of ECM.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: November 2, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Sreerama Shetty, Steven Idell
  • Patent number: 11155580
    Abstract: This invention is generally related to small proteins, such as miniature proteins, including avian pancreatic polypeptide (aPP), modified so that the small proteins reach the cytosol. In some embodiments, the modified protein molecules deliver an associated cargo molecule to the cytosol. Other embodiments of the invention relate to modified protein fusion molecules that reach the cytosol.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: October 26, 2021
    Assignee: Yale University
    Inventors: Alanna Schepartz Shrader, Jacob S. Applebaum, Jonathan R. LaRochelle
  • Patent number: 11154593
    Abstract: The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: October 26, 2021
    Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
  • Patent number: 11155577
    Abstract: In one aspect, the invention relates to compositions comprising stapled peptides, methods of making same, pharmaceutical compositions comprising same, and methods of treating various diseases, including, but not limited to, metabolic disorders such as diabetes, and cancers. The disclosed compounds comprise stapled peptides, including, but not limited to, stapled glucagon, axin, and p53 peptide homologues, which are useful as therapeutic agents for a variety of diseases as disclosed herein. The disclosed methods are useful in the preparation of a variety of stapled peptides, including stapled peptide homologues of glucagon, axin, and p53. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: October 26, 2021
    Assignee: University of Utah Research Foundation
    Inventors: Danny Hung-Chieh Chou, Yuanxiang Wang
  • Patent number: 11147879
    Abstract: The present invention is directed to the following: methods of treating or preventing stent thrombosis using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; methods of reducing mortality in a subject undergoing stent implantation using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; medicaments comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation; pharmaceutical compositions comprising cangrelor and bivalirudin; and methods of preparing a medicament comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: October 19, 2021
    Assignee: Chiesi Farmaceutici S.p.A
    Inventors: Clive Arthur Arculus-Meanwell, Simona Skerjanec
  • Patent number: 11150233
    Abstract: Described herein are nanopore protein conjugates that can be used in DNA sequencing reactions. The nanopore protein conjugates includes a nanopore protein monomer that is joined to a DNA binding domain. The nanopore protein monomer is available to oligomerize with other nanopore protein monomers, while the DNA binding domain is available to bind to a template DNA strand. In certain examples, the nanopore protein monomer is an alpha-hemolysin monomer or variant thereof and the DNA binding domain is an Sso7d protein or variant thereof, such as an Sso7d-like protein. Also provided are nanopore protein assemblies incorporating the nanopore protein conjugates, along with methods of using the nanopore protein assemblies in sequencing reactions.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: October 19, 2021
    Assignee: Roche Sequencing Solutions, Inc.
    Inventors: Timothy Craig, Corissa Harris, Matt Dipetro, Mark Ambroso, Yaozhong Zou, Marshall Porter, Issa Delkaninia, Alexxa Noble, James Fairman, Wiseley Wu, Kapil Bajaj, Giovanni Bellesia, Seong-Ho Shin
  • Patent number: 11141489
    Abstract: The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-L-Y—R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising the conjugate or the pharmaceutically acceptable salt thereof as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: October 12, 2021
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Michael Wagner, Thomas Olpp, Nino Meyer, Martin Bossart, Andreas Evers, Peyman Sakhaii, Pradeep K. Dhal, Paul Konowicz, James E. Stefano, Nils Poth
  • Patent number: 11142549
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: October 12, 2021
    Assignee: Bausch Health Ireland Limited
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Patent number: 11141389
    Abstract: Methods are provided for treatment of cancer cells, in a regimen comprising contacting the cancer cells with an inhibitor on NGly1, optionally in combination with a direct proteasome inhibitor.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: October 12, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Carolyn Ruth Bertozzi, Frederick Tomlin, Ulla Gerling-Driessen
  • Patent number: 11136349
    Abstract: Synthetic methods are described herein operable to efficiently produce a wide variety of molecular species through conjugate additions via decarboxylative mechanisms. For example, methods of functionalization of peptide residues are described, including selective functionalization of peptide C-terminal residues. In one aspect, a method of peptide functionalization comprises providing a reaction mixture including a Michael acceptor and a peptide and coupling the Michael acceptor with the peptide via a mechanism including decarboxylation of a peptide reside.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: October 5, 2021
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: David MacMillan, Daniel Novoa, Stefan McCarver
  • Patent number: 11136372
    Abstract: The disclosure provides apolipoprotein C-II (apoC-II) mimetic peptides and methods for treating hypertriglyceridemia in a patient with an effective amount of an apoC-II mimetic peptide.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: October 5, 2021
    Assignees: The United States of America, as represented by the Secretary, Dept. of Health & Human Services, Novo Nordisk A/S
    Inventors: Alan Thomas Remaley, Soumitra Shanker Ghosh, Madhav N. Devalaraja, Chih-Hung Lo, Denis O. Sviridov, Anna Wolska